Table 1.
PDX model summary.
| Experiment | PDX ID | Patient History | Cytogenetics | Blina Response | Mouse Strain | UCB Transplant | PDX Cell# | PDX Treatments |
|---|---|---|---|---|---|---|---|---|
| Expt#1 | ALL #1 | Infant bi-lineage leukemia; relapse w/B-ALL post-HSCT | t(6;11) | PD; CD19+ | NSGS | 8.0M WBCs w/OKT3, IV | 3.0M | Blina 2X per day ip (4 weeks), Pembro 1st and 3rd Monday |
| Expt#2 | ALL #2 | B-ALL; early marrow relapse | t(1;19) | PD; CD19+ | NSGS | 7.0M WBCs w/OKT3, IV | 2.5M | Blina 2X per day ip (2 weeks), Pembro 1st Monday |
| Expt#3 | ALL #3 | Ph+(T315I) B-ALL, MRD negative post-Blina; relapse post-HSCT | t(9;22) | CR; later CD19+ relapse post-HSCT | NRGS | 8.0M WBCs w/OKT3, IV | 1.0M | Blina 1X per day ip (4 weeks), Pembro 1st and 3rd Monday |
| Expt#4 | ALL #4 | Infant B-ALL; primary refractory disease | t(4;11) | PD; CD19- | NRGS | 6.3M WBCs w/OKT3, IV | 3.0M | Blina 1X per day ip (4 weeks), Pembro 1st and 3rd Monday |
PDX, patient-derived xenograft; ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplant; Ph, Philadelphia chromosome; Blina, blinatumomab; PD, progressive disease; CR, complete remission; WBC, white blood cell; UCB, umbilical cord blood; Pembro, pembrolizumab.